Sona Dolsenhe
Family · Jacksonville, FLNPI 1104434901
Payments from drug & device makers
Across 262 payments — averaging $20.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$794
- Novo Nordisk$611
- Amgen$589
- Bayer$521
- Lilly USA, LLC$423
- AbbVie$253
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,455100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 34 | $794 |
| Novo Nordisk | 30 | $611 |
| Amgen | 24 | $589 |
| Bayer | 30 | $521 |
| Lilly USA, LLC | 22 | $423 |
| AbbVie | 11 | $253 |
| Idorsia Pharmaceuticals US Inc | 12 | $209 |
| GSK | 11 | $201 |
| Johnson & Johnson | 7 | $200 |
| Exact Sciences | 10 | $182 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $181 |
| Novartis | 10 | $180 |
| Pfizer | 8 | $164 |
| Sanofi-aventis U.S. LLC | 7 | $137 |
| Ionis Pharmaceuticals, Inc. | 4 | $84 |
| Boehringer Ingelheim | 4 | $81 |
| Janssen Scientific Affairs, LLC | 2 | $76 |
| Corcept Therapeutics | 3 | $72 |
| Dexcom, Inc. | 4 | $71 |
| Merck | 4 | $65 |
| Medtronic | 3 | $64 |
| Mannkind Corporation | 1 | $60 |
| Astellas Pharma US Inc | 3 | $50 |
| Regeneron Healthcare Solutions, Inc. | 1 | $27 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Irhythm Technologies, Inc. | 1 | $18 |
| Ascensia Diabetes Care US Inc. | 1 | $17 |
| Philips North America LLC | 1 | $17 |
| Cequr Corporation | 1 | $16 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
| Convatec Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,455 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 43 | $77,822 |
| FarxigaDapagliflozin Propanediol | 51 | $64,454 |
| EliquisApixaban | 52 | $50,186 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $45,365 |
| XareltoRivaroxaban | 36 | $36,849 |
| Repatha SureclickEvolocumab | 27 | $25,833 |
| JardianceEmpagliflozin | 23 | $25,290 |
| IsentressRaltegravir Potassium | 12 | $23,547 |
| MounjaroTirzepatide | 12 | $21,814 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $14,639 |
| Piroxicam | 18 | $10,260 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $9,420 |
| JanuviaSitagliptin Phosphate | 12 | $6,693 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $6,090 |
| Rosuvastatin Calcium | 483 | $5,103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $794 | $79,09368 claims |
| Novo NordiskOzempic | $611 | $77,82243 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $201 | $54,78553 claims |
| PfizerEliquis | $164 | $50,18652 claims |
| Johnson & JohnsonXarelto | $200 | $36,84936 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $81 | $31,38036 claims |
| MerckIsentress, Januvia | $65 | $30,23924 claims |
| Lilly USA, LLCMounjaro | $423 | $21,81412 claims |
| AbbVieSynthroid | $253 | $2,19225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in Jacksonville
- Leighanne MeadeJacksonville$98K
- Jori TaylorJacksonville$48K
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.